Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Pfizer and BioNTech released more human data Friday indicating the omicron BA.5 boosters perform better than the old Covid shots. Stream NBC 5 for free, 24/7, wherever you are. People older than 55 ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the launch of Viagra (sildenafil), CEO Albert Bourla said at the 44th Annual ...